Plasma adrenomedullin concentrations in patients with renovascular or malignant hypertension;La concentrazione di adrenomedullina plasmatica nei pazienti cou ipertensione renovascolare o maligna

Minerva Cardioangiologica

Volumn 52, Issue 4, 2004, Pages 313-322

  Caliumi, C ^a   Cianci, R ^a   Celi, M ^a   Cerci, S ^a   Cotesta, D ^a   Petramala, L ^a   Fontana, S ^a   Letizia, C ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Hypertension; Malignant hypertension; Peptides; Renin angiotensin system; Renovascular hypertension

Indexed keywords

ADRENOMEDULLIN; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; MALE; MALIGNANT HYPERTENSION; PLASMA RENIN ACTIVITY; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ADRENOMEDULLIN; ADULT; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; HYPERTENSION, RENOVASCULAR; MALE; MIDDLE AGED; PEPTIDES; RADIOIMMUNOASSAY; RENIN-ANGIOTENSIN SYSTEM;

EID: 4744355563     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-60.
2. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:6-10.
3. Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K et al. Haemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 1993;241:271-3.
4. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 1997;95:1214-21.
5. Ebara T, Miura K, Okumura M, Matsuura T, Kim S, Yukimura T et al. Effect of adrenomedullin on renal hemodynamics and functions in dogs. Eur J Pharmacol 1994;263:69-73.
6. Nagaya N, Nishikimi T, Horio T, Yoshihara F, Kanazawa A, Matsuo H et al. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am J Physiol 1999;276:R213-8.
7. Fukuhara M, Tsuchihashi T, Abe I, Fujishima M. Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. Am J Physiol 1995;269;R1289-93.
8. Kohno M, Hanehira T, Kano H, Horio T, Yokokawa K, Ikeda M et al. Plasma adrenomedullin concentrations in essential hypertension. Hypertension 1996;27: 102-7.
9. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 2001;19: 765-73.
10. Letizia C, De Toma G, Cerci S, Massa R, Coassin S, Subioli S et al. Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure. Blood Press 1998;7:19-23.
11. Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria RD et al. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res 2001;33:290-4.
12. Letizia C, Caliumi C, Delfini E, Celi M, Sibiol S, Diacinti D et al. Adrenomedullin concentrations are elevated in plasma of patients with primary hyperparathyroidism. Metabolism 2003;52:159-62.
13. Kitamura K, Ichiki Y, Tanaka M, Kawamoto M, Emura J, Sakakibara S et al. Immunoreactive adrenomedullin in human plasma. FEBS Lett 1994;341:288-90.
14. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94: 2158-61.
15. Yamaguchi T, Baba K, Doi Y, Yano K. Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. Life Sci 1995;56: 379-87.
16. Kita T, Kitamura K, Kuwasako K, Kawamoto M, Eto T. Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentrations in humans. J Hypertens 1998;16:2057-62.
17. Letizia C, Subioli S, Cerci S, Caliumi C, Verrelli C, Delfini E et al. High plasma adrenomedullin concentrations in patients with high-renin essential hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:126-9.
18. The six report of the Joint National Committee on prevention, detection evaluation and treatment of high blood pressure. Arch Intern Med 1997;157: 2413-46.
19. Detection, evaluation and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension. Arch Intern Med 1987;147: 820-9.
20. Pickering TG, Sos TA, Vaughan ED. In case DB, Sealey JE, Harshfield GA et al. Predictive value and changes of renin secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. Am J Med 1984;76:398-404.
21. Letizia C, Cerci S, Centanni M, De Toma G, Subioli S, Scuro L et al. Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment. Clin Endocrinol (Oxf) 1998;48: 145-8.
22. Sealey JE, Laragh JH. How to do a plasma renin assay. Cardiovasc Med 1977;2:1079-92.
23. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999;22:61-5.
24. Jensen BL, Kramer BK, Kurz A. Adrenomedullin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells. Hypertension 1997;29: 1148-55.
25. Andreis PG, Mazzocchi C, Rebuffat P, Nussdorfer GG. Effects of adrenomedullin and proadrenomedullin-N-terminal 20 peptide on rat zona glomerulosa. Life Sci 1997;60:1693-7.
26. Andreis PG, Tortorella G, Mazzocchi G, Nussdorfer GG, Proadrenomedullin N-terminal 20 peptide inhibits aldosterone secretion of human adrenocorti- cal and Conn's adenoma cells: comparison with adrenomedullin effects. J Clin Endocrinol Metab 1998;83: 253-7.
27. Nagaya N, Sato H, Nishikimi T. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2001;101:498-503.
28. Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormone, and urinary effects of adrenomedullin in infusion in essential hypertension. Hypertension 2000;36:588-93.
29. Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med 1985;3(6 Suppl):10-5.
30. Sugo S, Minamino N, Shoji H, Kangana K, Kitamurk K et al.: Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207:25-32.
31. Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H. Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett 1995;369: 311-4.
32. Uemura T, Kato J, Kuwasako K, Kitamura K, Kangawa K, Eto T. Aldosterone augments adrenomedullin production without stimulating proadrenomedullin N-terminal 20 peptide secretion in vascular smooth muscle cells. J Hypertens 2002;20:1209-14.
33. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S et al. Adrenomeullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002;105:106-11.
34. Ishiyama J, Kitamura K, Kato J, Sakata J, Kangawa K, Eto T. Changes in cardiac adrenomedullin concentration in renovascular hypertensive rats. Hypertens Res 1997;20:113-7.
35. Khan AI, Kato J, Ishiyama Y, Kitamura K, Kangawa K, Eto T. Effect of chronically infused adrenomedullin in two-kidney, one-clip hypertensive rats. Eur J Pharmacol 1997;333:187-90.